



UnitedHealthcare Pharmacy
Clinical Pharmacy Programs

Program Number	2023 P 1412-1
Program	Prior Authorization/Notification
Medication	Skyclarys™ (omaveloxolone)
P&T Approval Date	5/2023
Effective Date	8/1/2023; Oxford only: 8/1/2023

1. Background:

Skyclarys (omaveloxolone) is indicated for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older.

2. Coverage Criteria^a:

A. Initial Authorization

1. **Skyclarys** will be approved based on the following criterion:

- a. Diagnosis of Friedreich’s ataxia

Authorization will be issued for 12 months.

B. Reauthorization

1. **Skyclarys** will be approved based on the following criterion:

- a. Documentation of positive clinical response to **Skyclarys** therapy

Authorization will be issued for 12 months.

^a State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply.

3. Additional Clinical Rules:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.
- Supply limits and/or Medical Necessity may be in place.

4. References:

1. Skyclarys™ [package insert]. Plano, TX: Reata Pharmaceuticals, Inc.; February 2023.



Program	Prior Authorization/Notification - Skyclarys™ (omaveloxolone)
Change Control	
5/2023	New program.